Xeris Biopharma promotes Kevin McCulloch to President and COO

Xeris Biopharma Holdings, Inc.

Kevin McCulloch, former Chief Commercial Officer, was promoted to President and COO effective August 1, 2024.
McCulloch will receive an annual base salary of $520,000 and a target annual incentive of 50% of base salary.
He was granted 150,000 restricted stock units vesting over 3 years and 200,000 stock appreciation rights vesting at 2 years.
Severance includes 1.25x salary plus target incentive if terminated without cause, or 1.5x if within 12 months after a change in control.
McCulloch reports to CEO John Shannon and joined Xeris in 2018 as SVP of Global Operations and Business Development.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Kevin McCulloch

President and Chief Operating Officer

XERS · Xeris Biopharma Holdings, Inc.

Effective: 2024-08-01
Filed: August 2, 2024, 7:59 PM ET

The Board of Directors of Xeris Biopharma Holdings, Inc. (the “Company”) promoted Kevin McCulloch to be President and Chief Operating Officer of the Company, effective as of August 1, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kevin McCulloch changed role as President and Chief Operating Officer at Xeris Biopharma Holdings, Inc..

Action: promoted
Role: President and Chief Operating Officer

Exact text from the filing

The Board of Directors of Xeris Biopharma Holdings, Inc. (the “Company”) promoted Kevin McCulloch to be President and Chief Operating Officer of the Company, effective as of August 1, 2024.

View on SEC.gov

Xeris Biopharma Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001867096-24-000137

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.